TRV GP V, LLC 13F Portfolio

CIK 1990717 Filing since Q4 2024 Q2 2026 filed Aug 7, 2026
Holdings as of Jun 30, 2026, from the 13F filed Aug 7, 2026.

Portfolio Snapshot

3 positions · Q2 2026

TRV GP V, LLC reported 3 positions worth $498.24M for the quarter ended Jun 30, 2026, up 24.2% on the prior quarter. It opened 0 new positions, added to 0, trimmed 1 and exited 0. Its largest holding is Rapport Therapeutics, Inc. at 52.5% of the portfolio.

Portfolio Value
$498.24M
+24.2% QoQ · +200.8% YoY
Positions
3
0 new · 0 sold out
Top 10 Concentration
100%
of portfolio value
Largest Position
RAPP 52.5%
Rapport Therapeutics, Inc.
Net Buying
-$35.62M
$0.00 bought · $35.62M sold
Turnover
0%
of the portfolio traded
Top Sector
Healthcare
100% of value
Track Record
7
quarters on file since Q4 2024

Portfolio Value & Positions

Value Positions

Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.

Sector Allocation

1 sectors
100%
Healthcare
Healthcare100%

Quarterly Buying & Selling

Bought Sold

Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.

Position Changes

How many positions were opened, added to, trimmed or closed each quarter.

Sector Allocation Over Time

Share of reported value in each sector at every quarter end.

HealthcareOther

Largest Buys

Q2 2026

No positions were added to this quarter.

Largest Sells

Q2 2026
Holding Change Change % Trade Value Weight
RAPP Rapport Therapeutics, Inc. -854.7K -12.0% $35.62M 52.53%

New Positions

Q2 2026

No new positions this quarter.

Closed Positions

Q2 2026

No positions were closed this quarter.

Holdings · Q2 2026

3 Positions

As ofJun 30, 2026
Value$498.24M
Top 10100%
Avg position$166.08M
# Activity
Showing all 3 positions 13F filings on SEC EDGAR

Tip. Select a row to see that position’s full history at Trv Gp V.

About TRV GP V, LLC’s 13F Portfolio

What are TRV GP V, LLC’s largest holdings?

As of its Q2 2026 13F filing, TRV GP V, LLC’s five largest positions were Rapport Therapeutics, Inc. (RAPP) at 52.5%, Septerna, Inc. (SEPN) at 41.8%, Maze Therapeutics, Inc. (MAZE) at 5.7% of the reported portfolio.

How much is TRV GP V, LLC’s portfolio worth?

TRV GP V, LLC reported a 13F portfolio worth $498.24M across 3 positions for Q2 2026. That is up 24.2% from the previous quarter.

What did TRV GP V, LLC sell in Q2 2026?

Its largest sales by value were Rapport Therapeutics, Inc. ($35.62M). It exited 0 positions entirely.

Where does this data come from?

From the Form 13F-HR reports TRV GP V, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.

Similar-Sized Institutions

by reported 13F value

13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.